Northwest Bioth Cmn (NWBO): Price and Financial Metrics


Northwest Bioth Cmn (NWBO): $1.29

0.02 (+1.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NWBO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 506

in industry

NWBO POWR Grades


  • Growth is the dimension where NWBO ranks best; there it ranks ahead of 81.78% of US stocks.
  • The strongest trend for NWBO is in Momentum, which has been heading down over the past 45 weeks.
  • NWBO ranks lowest in Momentum; there it ranks in the 11th percentile.

NWBO Stock Summary

  • NWBO's price/sales ratio is 831.8; that's higher than the P/S ratio of 99.1% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -0.09 for Northwest Biotherapeutics Inc; that's greater than it is for just 5.68% of US stocks.
  • Over the past twelve months, NWBO has reported earnings growth of 799.77%, putting it ahead of 97.16% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Northwest Biotherapeutics Inc are VLDR, UCL, WIMI, QNST, and CNET.
  • NWBO's SEC filings can be seen here. And to visit Northwest Biotherapeutics Inc's official web site, go to www.nwbio.com.

NWBO Valuation Summary

  • NWBO's price/earnings ratio is -2.4; this is 106.58% lower than that of the median Healthcare stock.
  • Over the past 239 months, NWBO's price/sales ratio has gone up 173.7.
  • NWBO's price/sales ratio has moved up 173.7 over the prior 239 months.

Below are key valuation metrics over time for NWBO.

Stock Date P/S P/B P/E EV/EBIT
NWBO 2021-08-31 831.8 -3.3 -2.4 -2.5
NWBO 2021-08-30 793.7 -3.1 -2.3 -2.4
NWBO 2021-08-27 825.5 -3.2 -2.4 -2.5
NWBO 2021-08-26 876.3 -3.4 -2.5 -2.6
NWBO 2021-08-25 857.2 -3.4 -2.5 -2.6
NWBO 2021-08-24 761.9 -3.0 -2.2 -2.3

NWBO Growth Metrics

  • Its 4 year cash and equivalents growth rate is now at -93.86%.
  • The 3 year revenue growth rate now stands at -65.24%.
  • The 4 year net income to common stockholders growth rate now stands at 104.54%.
Over the past 33 months, NWBO's revenue has gone up $479,000.

The table below shows NWBO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 1.374 -38.265 -474.108
2021-03-31 0.96 -37.802 -536.47
2020-12-31 1.291 -32.093 -529.821
2020-09-30 1.685 -27.868 -242.649
2020-06-30 2.062 -26.298 -54.795
2020-03-31 2.641 -29.647 3.376

NWBO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NWBO has a Quality Grade of C, ranking ahead of 29.4% of graded US stocks.
  • NWBO's asset turnover comes in at 0.045 -- ranking 330th of 677 Pharmaceutical Products stocks.
  • EDSA, BLCM, and BMRN are the stocks whose asset turnover ratios are most correlated with NWBO.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.045 1 1.610
2021-03-31 0.036 1 2.337
2020-12-31 0.061 1 3.470
2020-09-30 0.112 1 3.430
2020-06-30 0.190 1 1.815
2020-03-31 0.245 1 -0.306

NWBO Stock Price Chart Interactive Chart >

Price chart for NWBO

NWBO Price/Volume Stats

Current price $1.29 52-week high $2.51
Prev. close $1.27 52-week low $0.65
Day low $1.23 Volume 1,200,100
Day high $1.31 Avg. volume 1,825,319
50-day MA $1.25 Dividend yield N/A
200-day MA $1.44 Market Cap 1.13B

Northwest Bioth Cmn (NWBO) Company Bio


Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies. The company was founded in 1996 and is based in Bethesda, Maryland.


NWBO Latest News Stream


Event/Time News Detail
Loading, please wait...

NWBO Latest Social Stream


Loading social stream, please wait...

View Full NWBO Social Stream

Latest NWBO News From Around the Web

Below are the latest news stories about Northwest Biotherapeutics Inc that investors may wish to consider to help them evaluate NWBO as an investment opportunity.

UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the manufacturing facility in Sawston, UK has been submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA). The Company also provided a process update on the DCVax®-L Phase III Trial.

Yahoo | May 12, 2021

Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that development of the initial production capacity of the Company's Sawston, UK advanced manufacturing facility has been completed and the facility is now in the final stages of preparation for an application for certification by the UK Medicines and Health Products Regulatory Authority ("MHRA").

Yahoo | March 16, 2021

Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?

In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.

Yahoo | October 28, 2020

Northwest Biotherapeutics Announces Data Lock of Phase III Trial

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked.

Yahoo | October 5, 2020

Read More 'NWBO' Stories Here

NWBO Price Returns

1-mo 12.17%
3-mo -10.73%
6-mo -17.04%
1-year 46.61%
3-year 578.95%
5-year 104.76%
YTD -15.41%
2020 609.63%
2019 4.57%
2018 -12.63%
2017 -32.43%
2016 -89.12%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8033 seconds.